Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Certain pain-related pruritus descriptors may independently predict mental health outcomes, sleep disturbance, and QOL reduction in patients with AD.

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 10 Stocks Crash Hard Alongside Wall Street. Apogee Therapeutics fell by ...

Britain's manufacturing sector showed some signs of turning a corner in its long slump and businesses pushed up their prices ...

Apogee is pitching APG777 as a 'best-in-class' IL-13 inhibitor that could offer robust efficacy and less-frequent dosing than ...

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Adolescent patients with acne who had internalized stigma also had significantly lower quality of life, highlighting the need ...